既往未治疗的慢性淋巴细胞白血病患者氟达拉滨、环磷酰胺和利妥昔单抗治疗后的长期生存率

IF 0.1 Q4 HEMATOLOGY Iraqi Journal of Hematology Pub Date : 2021-07-01 DOI:10.4103/ijh.ijh_22_21
S. Mustafa, Ahmed K. Yassin, N. Mohammed, Rawand P. Shamoon, M. Karam, ShlanS Mohammad, L. Abdulrahman, Zhalla O. Ahmed, BryarSabah Rashid, Tavan I. Mahmood, Rozh-hatA Yousif, Kawa M. Hasan, Z. Mohamed, H. Getta, S. Jalal, D. Abdullah, Basil K. Abdulla, G. Numan, Ranan Karadagh
{"title":"既往未治疗的慢性淋巴细胞白血病患者氟达拉滨、环磷酰胺和利妥昔单抗治疗后的长期生存率","authors":"S. Mustafa, Ahmed K. Yassin, N. Mohammed, Rawand P. Shamoon, M. Karam, ShlanS Mohammad, L. Abdulrahman, Zhalla O. Ahmed, BryarSabah Rashid, Tavan I. Mahmood, Rozh-hatA Yousif, Kawa M. Hasan, Z. Mohamed, H. Getta, S. Jalal, D. Abdullah, Basil K. Abdulla, G. Numan, Ranan Karadagh","doi":"10.4103/ijh.ijh_22_21","DOIUrl":null,"url":null,"abstract":"BACKGROUND: Chronic lymphocytic leukemia (CLL) is characterized by a lower incidence rate in Iraq and Kurdistan as compared to Western countries. However, a good prognosis of CLL is dependable on diagnosis, risk stratification, and a better choice of an appropriate treatment regimen. AIM OF THE STUDY: To evaluate the effectiveness of fludarabine, cyclophosphamide, and rituximab (FCR) regimen in comparison to other chemotherapy regimens in the management of patients with CLL in Kurdistan region/Iraq. PATIENTS AND METHODS: A retrospective review study carried out in three cancer centers in the Kurdistan region of Iraq for the duration of 10 years through the period from January 1, 2010 to December 31, 2019, on 152 CLL patients. CLL was diagnosed according to the International Workshop on CLL. The treatment of CLL patients was either by FCR chemo-immunotherapy regimen or other chemotherapies. RESULTS: The FCR chemo-immunotherapy was the treatment of 38.8% of CLL patients, while 61.2% of CLL patients were treated by other chemotherapies. There was a significant association between younger age patients and the use FCR chemo-immunotherapy (P = 0.001). There was a significant association between a complete response and treatment by FCR chemo-immunotherapy (P = 0.02). The mean overall survival duration and progression-free survival of CLL patients treated by FCR chemo-immunotherapy were significantly longer than the mean survival time of CLL patients treated by other chemotherapies (P = 0.01). CONCLUSIONS: Complete response and survival of CLL patients treated by FCR chemo-immunotherapy were better than the complete response and survival of CLL patients treated by other chemotherapies.","PeriodicalId":53847,"journal":{"name":"Iraqi Journal of Hematology","volume":"10 1","pages":"139 - 145"},"PeriodicalIF":0.1000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term survival after fludarabine, cyclophosphamide, and rituximab treatment in previously untreated chronic lymphocytic leukemia patients\",\"authors\":\"S. Mustafa, Ahmed K. Yassin, N. Mohammed, Rawand P. Shamoon, M. Karam, ShlanS Mohammad, L. Abdulrahman, Zhalla O. Ahmed, BryarSabah Rashid, Tavan I. Mahmood, Rozh-hatA Yousif, Kawa M. Hasan, Z. Mohamed, H. Getta, S. Jalal, D. Abdullah, Basil K. Abdulla, G. Numan, Ranan Karadagh\",\"doi\":\"10.4103/ijh.ijh_22_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BACKGROUND: Chronic lymphocytic leukemia (CLL) is characterized by a lower incidence rate in Iraq and Kurdistan as compared to Western countries. However, a good prognosis of CLL is dependable on diagnosis, risk stratification, and a better choice of an appropriate treatment regimen. AIM OF THE STUDY: To evaluate the effectiveness of fludarabine, cyclophosphamide, and rituximab (FCR) regimen in comparison to other chemotherapy regimens in the management of patients with CLL in Kurdistan region/Iraq. PATIENTS AND METHODS: A retrospective review study carried out in three cancer centers in the Kurdistan region of Iraq for the duration of 10 years through the period from January 1, 2010 to December 31, 2019, on 152 CLL patients. CLL was diagnosed according to the International Workshop on CLL. The treatment of CLL patients was either by FCR chemo-immunotherapy regimen or other chemotherapies. RESULTS: The FCR chemo-immunotherapy was the treatment of 38.8% of CLL patients, while 61.2% of CLL patients were treated by other chemotherapies. There was a significant association between younger age patients and the use FCR chemo-immunotherapy (P = 0.001). There was a significant association between a complete response and treatment by FCR chemo-immunotherapy (P = 0.02). The mean overall survival duration and progression-free survival of CLL patients treated by FCR chemo-immunotherapy were significantly longer than the mean survival time of CLL patients treated by other chemotherapies (P = 0.01). CONCLUSIONS: Complete response and survival of CLL patients treated by FCR chemo-immunotherapy were better than the complete response and survival of CLL patients treated by other chemotherapies.\",\"PeriodicalId\":53847,\"journal\":{\"name\":\"Iraqi Journal of Hematology\",\"volume\":\"10 1\",\"pages\":\"139 - 145\"},\"PeriodicalIF\":0.1000,\"publicationDate\":\"2021-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Iraqi Journal of Hematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ijh.ijh_22_21\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iraqi Journal of Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijh.ijh_22_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:与西方国家相比,慢性淋巴细胞白血病(CLL)在伊拉克和库尔德斯坦的发病率较低。然而,CLL的良好预后依赖于诊断、风险分层和更好地选择合适的治疗方案。研究目的:评价氟达拉滨、环磷酰胺和利妥昔单抗(FCR)方案与其他化疗方案在库尔德斯坦地区/伊拉克治疗CLL患者中的有效性。患者和方法:在伊拉克库尔德斯坦地区的三个癌症中心进行了一项回顾性研究,为期10年,从2010年1月1日到2019年12月31日,对152名慢性淋巴细胞白血病患者进行了研究。CLL是根据国际CLL研讨会诊断的。CLL患者的治疗方案为FCR化疗-免疫治疗方案或其他化疗方案。结果:38.8%的CLL患者采用FCR化疗免疫治疗,61.2%的CLL患者采用其他化疗治疗。年龄较小的患者与使用FCR化疗免疫治疗之间存在显著相关性(P = 0.001)。完全缓解与FCR化疗免疫治疗之间存在显著相关性(P = 0.02)。FCR联合免疫治疗CLL患者的平均总生存期和无进展生存期明显长于其他化疗治疗CLL患者的平均生存期(P = 0.01)。结论:FCR联合免疫治疗CLL患者的完全缓解期和生存期优于其他化疗治疗CLL患者的完全缓解期和生存期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Long-term survival after fludarabine, cyclophosphamide, and rituximab treatment in previously untreated chronic lymphocytic leukemia patients
BACKGROUND: Chronic lymphocytic leukemia (CLL) is characterized by a lower incidence rate in Iraq and Kurdistan as compared to Western countries. However, a good prognosis of CLL is dependable on diagnosis, risk stratification, and a better choice of an appropriate treatment regimen. AIM OF THE STUDY: To evaluate the effectiveness of fludarabine, cyclophosphamide, and rituximab (FCR) regimen in comparison to other chemotherapy regimens in the management of patients with CLL in Kurdistan region/Iraq. PATIENTS AND METHODS: A retrospective review study carried out in three cancer centers in the Kurdistan region of Iraq for the duration of 10 years through the period from January 1, 2010 to December 31, 2019, on 152 CLL patients. CLL was diagnosed according to the International Workshop on CLL. The treatment of CLL patients was either by FCR chemo-immunotherapy regimen or other chemotherapies. RESULTS: The FCR chemo-immunotherapy was the treatment of 38.8% of CLL patients, while 61.2% of CLL patients were treated by other chemotherapies. There was a significant association between younger age patients and the use FCR chemo-immunotherapy (P = 0.001). There was a significant association between a complete response and treatment by FCR chemo-immunotherapy (P = 0.02). The mean overall survival duration and progression-free survival of CLL patients treated by FCR chemo-immunotherapy were significantly longer than the mean survival time of CLL patients treated by other chemotherapies (P = 0.01). CONCLUSIONS: Complete response and survival of CLL patients treated by FCR chemo-immunotherapy were better than the complete response and survival of CLL patients treated by other chemotherapies.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
相关文献
二甲双胍通过HDAC6和FoxO3a转录调控肌肉生长抑制素诱导肌肉萎缩
IF 8.9 1区 医学Journal of Cachexia, Sarcopenia and MusclePub Date : 2021-11-02 DOI: 10.1002/jcsm.12833
Min Ju Kang, Ji Wook Moon, Jung Ok Lee, Ji Hae Kim, Eun Jeong Jung, Su Jin Kim, Joo Yeon Oh, Sang Woo Wu, Pu Reum Lee, Sun Hwa Park, Hyeon Soo Kim
具有疾病敏感单倍型的非亲属供体脐带血移植后的1型糖尿病
IF 3.2 3区 医学Journal of Diabetes InvestigationPub Date : 2022-11-02 DOI: 10.1111/jdi.13939
Kensuke Matsumoto, Taisuke Matsuyama, Ritsu Sumiyoshi, Matsuo Takuji, Tadashi Yamamoto, Ryosuke Shirasaki, Haruko Tashiro
封面:蛋白质组学分析确定IRSp53和fastin是PRV输出和直接细胞-细胞传播的关键
IF 3.4 4区 生物学ProteomicsPub Date : 2019-12-02 DOI: 10.1002/pmic.201970201
Fei-Long Yu, Huan Miao, Jinjin Xia, Fan Jia, Huadong Wang, Fuqiang Xu, Lin Guo
来源期刊
自引率
0.00%
发文量
0
审稿时长
17 weeks
期刊最新文献
FMS-like tyrosine kinase 3 internal tandem duplication mutation in patients with acute myeloid leukemia in Kurdistan region/Iraq Biochemical and breakpoint cluster region-c-ABL oncogene 1 polymorphism study among Iraqi patients with chronic myeloid leukemia Subsets of natural killer cells in chronic myeloid leukemia and their relation with some inflammatory cytokines Myelofibrosis secondary to Hodgkin’s lymphoma: A case report The study of long noncoding RNA SNHG5 and PANDAR genes expression in newly diagnosed egyptian adult acute myeloid leukemia patients
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1